[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou 8th People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":224},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,70,90,113,135,160,178,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100588895","comparison-of-taf-and-tdf-in-preventing-mother-to-child-transmission-of-hbv-in-pregnancies-with-high-viral-loads-100588895",false,"NCT06947356","Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads","A Multicenter, Prospective, Open-label, Non-inferiority Randomized Controlled Study on the Efficacy of Tenofovir Alafenamide Fumarate vs. Tenofovir Disoproxil Fumarate in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Pregnant Women With High Viral Loads","Inclusion Criteria:\n\n1. Pregnant women aged between 20 and 40 years old\n2. Pregnancy duration between 20 to 28 weeks (screening for eligible patients can start from the 20th week of gestation)\n3. Clinically diagnosed with compensated chronic hepatitis B, HBsAg positive for more than 6 months, with clinical history, signs, and test results consistent with compensated chronic hepatitis B\n4. HBsAg and HBeAg positive in maternal serum during screening\n5. PCR testing shows maternal serum HBV DNA levels exceeding 200,000 IU\u002FmL\n6. Subjects voluntarily agree to undergo treatment according to the study design's drug treatment plan and all other research requirements, and patients consent to strictly avoid pregnancy within 28 weeks postpartum\n7. Patients and their husbands (the biological parents of the child) understand the risks and voluntarily participate in the study. The mother must participate voluntarily and sign a written informed consent document before participating in the study.\n\nExclusion Criteria:\n\n1. Creatinine clearance \\\u003C 100 mL\u002Fmin (calculated using the Cockcroft-Gault method based on serum creatinine and ideal body weight), or hypophosphatemia (below normal range).\n2. History of adverse renal reactions induced by Adefovir or history of Adefovir resistance.\n3. Meeting one of the following criteria: hemoglobin \\\u003C 80 g\u002FL, neutrophil count \\\u003C 1000\u002FμL, ALT \\> 5 times the upper limit of normal, total bilirubin \\> 20 mg\u002FL, albumin \\\u003C 25 g\u002FL, abnormal levels of creatinine or urea nitrogen.\n4. Pregnant women with a history of miscarriage, history of giving birth to a child with congenital malformations, or history of fetal infection with hepatitis B virus.\n5. The biological father of the current pregnancy has chronic hepatitis B.\n6. The investigator assesses that the subject has significant kidney, cardiovascular, pulmonary, or neurological diseases that affect their participation in the study.","FEMALE","20 Years","40 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"NA","The main objective of this study is to compare the mother-to-infant transmission rates of hepatitis B between pregnant women receiving treatment with tenofovir alafenamide and those receiving treatment with tenofovir disoproxil fumarate, after administering the hepatitis B vaccine and hepatitis B immunoglobulin to their infants at birth. Investigators define the mother-to-infant transmission rate of hepatitis B as the proportion of infants who are HBsAg positive and have serum HBV DNA \\>20 IU\u002FmL at 28 weeks of age among all live births in the experimental group.\n\nAdditionally, this study will also compare the incidence of congenital defects\u002Fmalformations in infants born to mothers treated with tenofovir alafenamide and tenofovir disoproxil fumarate during the perinatal period to assess drug safety.",[27],"Hepatitis B","RECRUITING","2025-05-03",{"date":31,"type":32},"2025-05-07","ACTUAL",{"date":29,"type":32},{"date":35,"type":21},"2028-05-01",{"name":37,"class":38},"Guangzhou 8th People's Hospital","OTHER",10,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100527289","clinical-application-of-cytokine-adsorption-technique-in-aids-patients-with-severe-pneumonia-andor-septic-shock-100527289","NCT06145828","Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and\u002For Septic Shock","Clinical Application of Cytokine Adsorption Technology in AIDS Patients With Severe Pneumonia and\u002For Septic Shock: An Observational Study.","Inclusion Criteria:\n\n1. Confirmed HIV infection;\n2. Progression to AIDS stage: CD4+ count \\\u003C200 cells\u002Ful and\u002For occurrence of AIDS opportunistic infections;\n3. Age between 18 and 65 years;\n4. Meeting the diagnosis of severe pneumonia or septic shock:\n\n   1. The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia;\n   2. The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's \"Chinese Guidelines for the Emergency Treatment of Sepsis\u002FSeptic Shock (2018).\n\nExclusion Criteria:\n\n1. Coexisting central nervous system lesions, severe liver disease, or cirrhosis;\n2. Concurrent AIDS-related or unrelated tumors;\n3. Women who are pregnant or breastfeeding;\n4. Severe underlying diseases of the heart, lungs, liver, kidneys, etc.;\n5. Alcohol abuse or drug use;\n6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial.","ALL","18 Years","65 Years",{"count":51,"type":21},60,"OBSERVATIONAL","Observing the Real-World Application Effectiveness of Cytokine Immune Adsorption Technology in AIDS Patients with Severe Pneumonia or septic shock.",[55,56],"AIDS Pneumonia","Septic Shock",[58,59,56,60],"AIDS","Severe Pneumonia","Cytokine Adsorption Technique","2023-11-17",{"date":63,"type":32},"2023-11-24",{"date":65,"type":32},"2023-10-23",{"date":67,"type":21},"2027-10-23",{"name":37,"class":38},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":76,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":89,"locationsCount":69},"100527290","metagenomic-next-generation-sequencing-guides-anti-infection-strategies-100527290","NCT06145841","Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies","Clinical Application of Metagenomic Next-Generation Sequencing-Guided Anti-Infection Strategies in AIDS Patients With Severe Pneumonia and\u002For Sepsis",{"count":77,"type":21},400,"This study aims to observe the effectiveness of clinical application in guiding anti-infection treatments in AIDS patients with severe pneumonia and\u002For sepsis using Metagenomic Next-Generation Sequencing-based technology in the real world",[58,80,81],"Pneumonia","Sepsis, Neonatal",[58,83,84,85],"severe pneumonia","Sepsis","metagenomic next-generation sequencing",{"date":63,"type":32},{"date":65,"type":32},{"date":67,"type":21},{"name":37,"class":38},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":97,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":69},"100526626","risk-identification-factors-for-pulmonary-function-impairment-in-aids-patients-recovered-from-severe-pneumonia-100526626","NCT06137196","Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia","Study on Risk Identification Factors for Lung Function Impairment in AIDS Patients Recovered From Severe Pneumonia","Inclusion Criteria:\n\n1. Confirmed HIV infection;\n2. Progression to the AIDS stage: CD4+ count \\\u003C200 cells\u002FµL and\u002For occurrence of opportunistic infections associated with AIDS;\n3. Age between 18 to 65 years;\n4. Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA).\n\nExclusion Criteria:\n\n1. Concurrent central nervous system lesions, severe liver disease, or cirrhosis;\n2. Concurrent AIDS-related or non-related tumors;\n3. Women who are pregnant or breastfeeding;\n4. Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.;\n5. Alcohol abuse or drug use;\n6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial",{"count":98,"type":21},100,"Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.",[58,80],[58,102,103,104],"Severe pneumonia","Lung function","Predictive factors","2023-11-13",{"date":107,"type":32},"2023-11-18",{"date":109,"type":32},"2023-11-01",{"date":111,"type":21},"2027-11-01",{"name":37,"class":38},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":120,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":69},"100515236","functional-cure-of-hepatitis-b-in-hivhbv-co-infected-patients-100515236","NCT05988879","Functional Cure of Hepatitis B in HIV\u002FHBV Co-infected Patients","A Clinical Research on Functional Cure Strategies for Hepatitis B Among HIV\u002FHBV Co-infected Patients in China","Inclusion Criteria:\n\n1. Age 18-65 years old, gender unrestricted.\n2. Meeting the People's Republic of China Health Industry Standard (WS293-2008) - \"AIDS and HIV Infection Diagnostic Criteria\", confirmed as HIV-1 infected.\n3. HBsAg positive for more than 6 months.\n4. At least 1 year of ART treatment prior to screening, and currently undergoing ART treatment with HBsAg \\\u003C1000IU\u002FmL, HBeAg negative, HBV DNA \\\u003C100IU\u002Fml, CD4+T lymphocyte count \\>200 cells\u002FμL and HIV-RNA\\\u003C20 copies\u002Fml.\n\nExclusion Criteria:\n\n1. Pregnant, nursing, planning pregnancy, or with severe mental disorders or uncontrolled epilepsy.\n2. Co-infected with Hepatitis A, C, D, or E viruses.\n3. With other chronic liver diseases like autoimmune hepatitis, drug-induced hepatitis, alcoholic hepatitis, genetic metabolic liver diseases, or moderate to severe fatty liver.\n4. With autoimmune diseases like rheumatoid arthritis, psoriasis, or lupus.\n5. Post organ transplant, planning organ transplant, diagnosed or suspected of liver cancer or other malignant tumors, or undergoing immunosuppressive treatment.\n6. With severe diseases of heart, lungs, kidneys, brain, retinal disorders, or uncontrolled hypertension or diabetes.\n7. Excessive alcohol (average daily alcohol intake \\>40g for men, \\>20g for women) or drug users.\n8. Participated in other interventional trials within the last three months, or other situations deemed inappropriate for inclusion by researchers.",{"count":51,"type":21},"Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV\u002FHBV co-infected patients",[58,27],[124,125,126],"HIV\u002FHBV co-infection","Functional cure","Interferon","2023-08-10",{"date":129,"type":32},"2023-08-14",{"date":131,"type":32},"2023-08-02",{"date":133,"type":21},"2028-08-02",{"name":37,"class":38},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":69},"100353652","dolutegravir-plus-lamivudine-simplified-therapy-100353652","NCT03884673","Dolutegravir Plus Lamivudine Simplified Therapy","Real World Study: Dolutegravir Plus Lamivudine Simplified Therapy in Treatment Experienced HIV-1 Patients","Inclusion Criteria:\n\n1. Age (\\> 18 years), male and female;\n2. HIV-1 infected;\n3. Using a standard three-drug-based regimen for at least 24 weeks. Based on clinical decision making\\* decide if patients can be treated with the DTG+3TC simplified scheme for a variety of reasons, such as (but not limited to): patients cannot tolerate the conventional three-drug treatment scheme, renal insufficiency, osteoporosis, bone marrow suppression and for other reasons patients cannot use the conventional three-drug treatment scheme;\n4. Initial HIV-1 RNA viral load and CD4 cell count were unlimited.\n5. CD4 can be monitored at least three times in the first year (including baseline, 24 weeks of treatment and 48 weeks of treatment). After the first year, CD4 can be detected at least once every six months.\n6. State Informed Consent for Free Treatment has been signed;\n7. Good compliance and signing Informed Consent\n\n(\\* Reference criteria: Refer to APSIRE study, creatinine clearance rate (\\> 50 mL\u002Fmin), no DTG\u002F3TC allergy history, HBsAg negative, no chronic liver disease, no severe liver damage, no pregnancy during the study)\n\nExclusion Criteria:\n\n1. Has participated in other clinical trials of HIV vaccine or other drug trials in the past three months;\n2. Researchers decide if patients could\u002Fnot complete the scheduled follow-up (factors to consider such as weak, poor compliance, etc.).\n3. Has a clear history of DTG or 3TC allergy;\n4. HBsAg and\u002For HBV-DNA positive;\n5. Pregnancy during the study period.",{"count":143,"type":21},300,"Dolutegravir (DTG) is one type of integrase inhibitor, lamivudine (3TC) is one type of reverse transcriptase inhibitor, both of which are HIV medicine prevents HIV from self-multiplying, reduces the viral load. The data of the existing randomized controlled clinical studies show that the simplified two-drug DTG-based regimen is similar to the three-drug regimen in terms of efficacy, but there are no relevant data and reports on the efficacy and safety of DTG+3TC in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of the DTG + 3TC regimen for HIV-infected patients in real clinical environment, to guide clinical application, and to provide a theoretical basis for the selection of simplified schemes for the formulation of guidelines.\n\nThis study was done to see if the combination of two anti-HIV medicines, dolutegravir (DTG, Tivicay) and lamivudine (3TC, Epivir) taken once a day, provide a safe, effective, and well-tolerated treatment for HIV.",[146],"HIV\u002FAIDS",[148,149,150,151],"DTG + 3TC Simplified Therapy","Simplified Therapy Regimen","Real World Study","HIV-1-infected patients","2022-09-13",{"date":154,"type":32},"2022-09-14",{"date":156,"type":32},"2019-01-01",{"date":158,"type":21},"2030-12-31",{"name":37,"class":38},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":69},"100332108","simplified-treatment-of-anti-retrovirus-in-china-c-star-100332108","NCT03603977","Simplified Treatment of Anti-retrovirus in China (C-STAR)","A Simplified Therapy Regimen Study of Lopinavir and Ritonavir Combined With Lamivudine for HIV-1 Infected Patients in the Real World of China","Inclusion Criteria:\n\n1. HIV-1 infection confirmed\n2. Agree to use simplified therapy regimen.\n3. Agree to detect CD4 count at least once per half a year\n\nExclusion Criteria:\n\n1. Have participated in HIV vaccine clinical trial or other drug trials in the past three months.\n2. Patients who could not complete the scheduled follow-up (such as weakness and poor compliance).\n3. Patients who have the history of resistance or allergy to LPV\u002Fr or 3TC.",{"count":168,"type":21},600,"To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.",[146],[149,150,151],{"date":154,"type":32},{"date":174,"type":32},"2017-11-01",{"date":176,"type":21},"2030-10-31",{"name":37,"class":38},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":200,"locationsCount":69},"100304218","phase-1-the-effect-of-chimeric-antigen-receptor-car-t-cell-therapy-on-the-reconstitution-of-hiv-specific-immune-function-100304218","NCT03240328","The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function","The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function","Inclusion Criteria:\n\n1. HIV infection confirmed.\n2. Receiving cART more than 12 months.\n3. HIV viral-load \\\u003C 50 copies\u002Fml and CD4 cell count more than 350 cells\u002Ful.\n4. Without serious liver, heart, liver and kidney diseases.\n5. The subjects know about the study and volunteer to attend the research and sign the informed consent.\n\nExclusion Criteria:\n\n1. With active HBV or HCV infection, or serious opportunistic infections.\n2. With serious chronic disease such like diabetes, the mental illness,et al\n3. History of suffering from pancreatitis during cART.\n4. Pregnant or breast-fed.\n5. With poor adherence.\n6. Unable to complete follow up.","60 Years",{"count":187,"type":21},40,[189],"PHASE1","To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.",[146],[193,194,195],"CAR-T HIV therapy","immunotherapy","function cure",{"date":154,"type":32},{"date":198,"type":32},"2017-10-04",{"date":158,"type":21},{"name":37,"class":38},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":47,"minAge":209,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":69},"100413702","observational-study-on-patients-with-hivaidsospwh-100413702","NCT04667026","Observational Study on Patients With HIV\u002FAIDS(OSPWH)","Observational Study of Antiretroviral Therapy Cohort in Patients With HIV\u002FAIDS","OSPWH","Inclusion Criteria:\n\n* Patients has a history of diagnosis of HIV.\n* Receiving antiretroviral therapy.\n* Good treatment compliance.\n\nExclusion Criteria:\n\n* Aged less than 14 years of old.","14 Years",{"count":211,"type":21},15000,"To establish a follow-up cohort of antiretroviral therapy(ART) for patients with HIV\u002FAIDS, to observe the ART efficacy and adverse reactions, complications in the process of ART, as well as mortality and causes of death, so as to provide basis for further improving ART efficacy and quality of life of the patients.",[214],"HIV Infections",[146,216],"ART","2022-09-12",{"date":154,"type":32},{"date":220,"type":32},"2009-01-01",{"date":222,"type":21},"2031-05-31",{"name":37,"class":38},""]